Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications

被引:25
|
作者
de Bruin, Renee C. G. [1 ]
Lougheed, Sinead M. [1 ]
van der Kruk, Liza [1 ]
Stam, Anita G. [1 ]
Hooijberg, Erik [2 ]
Roovers, Rob C. [3 ]
Henegouwen, Paul M. P. van Bergen En [3 ]
Verheul, Henk M. W. [1 ]
de Gruijl, Tanja D. [1 ]
van der Vliet, Hans J. [1 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Room 3A38,De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pathol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[3] Univ Utrecht, Fac Sci, Dept Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands
关键词
Nanobody; Single-domain antibody fragment; VHH; Gamma delta T cells; Flow cytometry; MACS; Immunocytochemistry; Immunotherapy; Cancer; DELTA T-CELLS; CANCER-IMMUNOTHERAPY; ANTIBODY FRAGMENTS; ANTIGEN RECEPTOR; ALBUMIN-BINDING; LIGHT-CHAINS; RECOGNITION; DOMAIN; PHOSPHOANTIGENS; MODULATION;
D O I
10.1016/j.clim.2016.06.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
V gamma 9V delta 2-T cells constitute the predominant subset of gamma delta-T cells in human peripheral blood and have been shown to play an important role in antimicrobial and antitumor immune responses. Several efforts have been initiated to exploit these cells for cancer immunotherapy, e.g. by using phosphoantigens, adoptive cell transfer, and by a bispecific monoclonal antibody based approach. Here, we report the generation of a novel set of V gamma 9V delta 2-T cell specific VHH (or nanobody). VHH have several advantages compared to conventional antibodies related to their small size, stability, ease of generating multispecific molecules and low immunogenicity. With high specificity and affinity, the anti-V gamma 9V delta 2-T cell receptor VHHs are shown to be useful for FACS, MACS and immunocytochemistry. In addition, some VHH were found to specifically activate V gamma 9V delta 2-T cells. Besides being of possible immunotherapeutic value, these single domain antibodies will be of great value in the further study of this important immune effector cell subset. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:128 / 138
页数:11
相关论文
共 50 条
  • [21] Vγ9Vδ2-T lymphocytes have impaired antiviral function in small-for-gestational-age and preterm neonates
    Li, Jinrong
    Li, Hong
    Mao, Huawei
    Yu, Meixing
    Feng, Ting
    Yang, Fan
    Fan, Yingying
    Lu, Qiao
    Shen, Chongyang
    Yin, Zhongwei
    Tu, Wenwei
    Mao, Meng
    CELLULAR & MOLECULAR IMMUNOLOGY, 2013, 10 (03) : 253 - 260
  • [22] Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity
    Stephen R. Mattarollo
    Tony Kenna
    Mie Nieda
    Andrew J. Nicol
    Cancer Immunology, Immunotherapy, 2007, 56 : 1285 - 1297
  • [23] BTLA, a key regulator of Vγ9Vδ2 T-cell proliferation
    Gertner-Dardenne, Julie
    Fauriat, Cyril
    Olive, Daniel
    ONCOIMMUNOLOGY, 2013, 2 (09)
  • [24] Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists
    Wiemer, David F.
    Wiemer, Andrew J.
    BIOCHEMICAL PHARMACOLOGY, 2014, 89 (03) : 301 - 312
  • [25] RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor
    Sebestyen, Zsolt
    Scheper, Wouter
    Vyborova, Anna
    Gu, Siyi
    Rychnavska, Zuzana
    Schiffler, Marleen
    Cleven, Astrid
    Cheneau, Coraline
    van Noorden, Martje
    Peigne, Cassie-Marie
    Olive, Daniel
    Lebbink, Robert Jan
    Oostvogels, Rimke
    Mutis, Tuna
    Schuurhuis, Gerrit Jan
    Adams, Erin J.
    Scotet, Emmanuel
    Kuball, Jurgen
    CELL REPORTS, 2016, 15 (09): : 1973 - 1985
  • [26] A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia
    de Weerdt, Iris
    Lameris, Roeland
    Ruben, Jurjen M.
    de Boer, Renate
    Kloosterman, Jan
    King, Lisa A.
    Levin, Mark-David
    Parren, Paul W. H., I
    de Gruijl, Tanja D.
    Kater, Arnon P.
    van der Vliet, Hans J.
    CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1744 - 1755
  • [27] Bacterial outer-membrane vesicles promote Vγ9Vδ2 T cell oncolytic activity
    Firth, Jack
    Sun, Jingjing
    George, Vaques
    Huang, Jian-Dong
    Bajaj-Elliott, Mona
    Gustafsson, Kenth
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [28] Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti-versus Pro-Tumoral Activities
    Xiang, Zheng
    Tu, Wenwei
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [29] Editorial: Vγ9Vδ2 T cells: triple costimulation goes the distance
    Sheridan, Brian S.
    Obar, Joshua J.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2016, 99 (04) : 515 - 517
  • [30] Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells
    Cui, Qu
    Shibata, Hironobu
    Oda, Asuka
    Amou, Hiroe
    Nakano, Ayako
    Yata, Kenichiro
    Hiasa, Masahiro
    Watanabe, Keiichiro
    Nakamura, Shingen
    Miki, Hirokazu
    Harada, Takeshi
    Fujii, Shiro
    Kagawa, Kumiko
    Takeuchi, Kyoko
    Ozaki, Shuji
    Matsumoto, Toshio
    Abe, Masahiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 94 (01) : 63 - 70